🇺🇸 Intralesional Triamcinolone in United States

5 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 5

Most-reported reactions

1. Cardiac Arrest — 1 report (20%)
2. Condition Aggravated — 1 report (20%)
3. Drug Ineffective — 1 report (20%)
4. Product Quality Issue — 1 report (20%)
5. Status Epilepticus — 1 report (20%)

Source database →

Frequently asked questions

Is Intralesional Triamcinolone approved in United States?

Intralesional Triamcinolone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Intralesional Triamcinolone in United States?

Centro Dermatológico Dr. Ladislao de la Pascua is the originator. The local marketing authorisation holder may differ — check the official source linked above.